Drug dosage adjustments according to renal function at hospital discharge

Annals of Pharmacotherapy

Volumn 40, Issue 7-8, 2006, Pages 1254-1260

  Van Dijk, Elisabeth A ^a,b   Drabbe, Nathalie R G ^a   Kruijtbosch, Martine ^c   De Smet, Peter A G M ^b,d  

^a VIECURI MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c SIR Institute for Pharmacy Practice Research   (Netherlands)

^d SIR Institute for Pharmacy Practice Research ^*

Author keywords

Dosage guidelines; Medication safety; Renal impairment; Serum creatinine

Indexed keywords

ALENDRONIC ACID; ALLOPURINOL; AMILORIDE; CREATININE; DIGOXIN; ENALAPRIL; ETRETIN; GLIMEPIRIDE; HYDROCHLOROTHIAZIDE; METFORMIN; NITROFURANTOIN; PRAVASTATIN; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG SAFETY; FEMALE; HOSPITAL DISCHARGE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CREATININE; DRUG MONITORING; FEMALE; HOSPITALIZATION; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PATIENT DISCHARGE; PHARMACEUTICAL PREPARATIONS;

EID: 33746983504     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G742     Document Type: Article

References (24)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-5.
2. Beijer HJ, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 2002;24:46-54.
3. Lagnaoui R, Moore N, Fach J, Longy-Boursier M, Begaud B. Adverse drug reactions in a department of systemic diseases-oriented internal medicine: prevalence, incidence, direct costs and avoidability. Eur J Clin Pharmacol 2000;56:181-6.
4. Peyriere H, Cassan S, Floutard E, et al. Adverse drug events associated with hospital admission. Ann Pharmacother 2003;37:5-11. DOI 10.1345/aph.1C126.
5. Winterstein AG, Sauer BC, Hepler CD, Poole C. Preventable drug-related hospital admissions. Ann Pharmacother 2002;36:1238-48. DOI 10.1345/aph.1A225
6. Seeger JD, Kong SX, Schumock GT. Characteristics associated with ability to prevent adverse drug reactions in hospitalized patients. Pharmacotherapy 1998;18:1284-9.
7. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2002;36:1331-6. DOI 10.1345/aph.1A333
8. Schiff GD, Klass D, Peterson J, Shah G, Bates DW. Linking laboratory and pharmacy: opportunities for reducing errors and improving care. Arch Intern Med 2003;163:893-900.
9. Kappel J, Calissi P. Nephrology: 3. Safe drug prescribing for patients with renal insufficiency. CMAJ 2002;166:473-7.
10. Matzke GR, Frye RF. Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity. Drug Saf 1997;16:205-31.
11. Jelliffe RW. Creatinine clearance: bedside estimate. Ann Intern Med 1973;79:604-5.
12. Bunn R, Ashley C. The renal drug handbook. Abingdon, UK: UK Renal Pharmacy Group, 1999.
13. Aronoff GR, Berns JS, Brier ME, et al. Drug prescribing in renal failure: dosing guidelines for adults. 4th ed. Philadelphia: American College of Physicians, American Society of Internal Medicine, 1999.
14. WINAp Geneesmiddelinformatiecentrum. Informatorium Medicamentorum. Koninklijke Nederlandse Maatschappij ter bevordering van de Pharmacie, 2005.
15. Micromedex Health Care Series, www.thomsonhc.com (accessed 2005 Mar 11).
16. Chertow GM, Lee J, Kuperman GJ, et al. Guided medication dosing for inpatients with renal insufficiency. JAMA 2001;286:2839-44.
17. Pillans PI, Landsberg PG, Fleming A-M, Fanning M, Sturtevant JM. Evaluation of dosage adjustment in patients with renal impairment. Int Med J 2003;33:10-3.
18. Salomon L, Deray G, Jaudon MC, et al. Medication misuse in hospitalized patients with renal impairment. Int J Qual Health Care 2003;15:331-5.
19. Salomon L, Levu S, Deray G, Launay-Vacher V, Brucker G, Ravaud P. Assessing residents' prescribing behavior in renal impairment. Int J Qual Health Care 2003;15:235-40.
20. Wasserfallen J, Livio F, Buclin T, Tillet L, Yersin B, Biollaz J. Rate, type, and cost of adverse drug reactions in emergency department admissions. Eur J Intern Med 2001;12:442-7.
21. Duncan L, Heathcote J, Djurdjev O, Levin A. Screening for renal disease using serum creatinine: who are we missing? Nephrol Dial Transplant 2001;16:1042-6.
22. Vidal L, Shavit M, Fraser A, Paul M, Leibovici L. Systematic comparison of four sources of drug information regarding adjustment of dose for renal function. BMJ 2005;331:263. Epub 19 May 2005.
23. Long CL, Raebel MA, Price DW, Magid DJ. Compliance with dosing guidelines in patients with chronic kidney disease. Ann Pharmacother 2004;38:853-8. Epub 30 Mar 2004. DOI 10.1345/aph.1D399
24. Bates DW, Miller EB, Cullen DJ, et al. Patient risk factors for adverse drug events in hospitalized patients. ADE Prevention Study Group. Arch Intern Med 1999;159:2553-60.